This study evaluates the feasibility and efficacy of the Samphire Guided Care (SGC) program
* a 12-week structured digital health program combining clinician-led onboarding, at-home neuromodulation using the Lutea tDCS device, neuromodulation coach support, and app-based symptom tracking - on work productivity, employee wellbeing, and quality of life in individuals experiencing mood and cognitive symptoms associated with menstruation, perimenopause, or menopause.
Self-identified female, aged 18-65 years at the time of enrollment
Basic English literacy
Able and willing to provide informed consent electronically
Residing in the United States
Pregnancy, breastfeeding, or actively planning pregnancy during the study period
History of epilepsy or seizure disorder
Severe or unstable neurological disease that, in the opinion of the study team, may increase risk or interfere with participation
Implanted electronic or metal devices in the head, neck, or brain region contraindicated for tDCS use
Samphire Group, Inc.
Lead sponsor